Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.02, 5.07, 7.01, 9.01 · 8-K

Standard BioTools Inc.

LABNASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders · Regulation FD Disclosure

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As disclosed in Item 5.07 of this Current Report on Form 8-K, at the Special Meeting (as defined below), the stockholders of Standard BioTools Inc.…

Filed Nov 19, 2026Accepted Nov 19, 2026, 5:00 PM ESTCIK 1162194Accession 0001140361-26-044934
Share

Company context

Standard BioTools Inc. (NASDAQ: LAB) is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team. The Company's established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn and YouTube™.

Current securities

Historical securities (1)

Recent company filings

  1. 425 filingNov 19, 2026
  2. 425 filingNov 16, 2026
  3. Other EventsNov 16, 2026
  4. SCHEDULE 13G/A - filed by MAK Capital Fund LP regarding STANDARD BIOTOOLS INC.Nov 16, 2026
  5. 10-Q filingNov 3, 2026

Registered securities in this filing

Standard BioTools Inc. · 8-K · Filed 2026-11-19

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common stock, $0.001 par value per share

Symbol
LAB
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: c20261119to20261119

Dimensions: Not supplied

Accession 000114036126044934 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 5.02, 5.07, 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As disclosed in Item 5.07 of this Current Report on Form 8-K, at the Special Meeting (as defined below), the stockholders of Standard BioTools Inc. (the “Company”) voted to approve the Post-Closing Equity Incentive Plan and the Post-Closing ESPP, each as defined in the Company’s definitive proxy statement/prospectus (the “Proxy Statement/Prospectus”), filed with the Securities and Exchange Commission (the “SEC”) on October 21, 2026 pursuant to Rule 424(b)(3) and forming part of the Company’s registration statement on Form S-4 (File No. 333-297560), which was declared effective by the SEC on October 21, 2026. The Post-Closing Equity Incentive Plan and the Post-Closing ESPP will become effective at the effective time of the Merger (as defined in the Proxy Statement/Prospectus) and are each contingent on the closing of the Merger. The material features of the Post-Closing Equity Incentive Plan and the Post-Closing ESPP are set forth in the Proxy Statement/Prospectus. Those summaries and the foregoing descriptions are qualified in their entirety by reference to the complete text of the Post-Closing Equity Incentive Plan and the Post-Closing ESPP, copies of which are filed as Exhibit 10.1 and Exhibit 10.2, respectively, to this Current Report on Form 8-K and incorporated in this Item 5.02 by reference.
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07. Submission of Matters to a Vote of Security Holders. On November 19, 2026, the Company held a virtual special meeting of stockholders (the “Special Meeting”) to vote on the proposals identified in the Proxy Statement/Prospectus. At the close of business on October 16, 2026, the record date for the Special Meeting, there were 394,711,296 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued and outstanding and entitled to vote at the Special Meeting. A total of 281,744,412 votes, or approximately 71.38% of the total voting power of the shares of the Company’s capital stock issued and outstanding and entitled to vote at the Special Meeting, were present virtually or represented by proxy at the Special Meeting, constituting a quorum. The following proposals are described in detail in the Proxy Statement/Prospectus. The final voting results for each of the matters submitted to a vote of the Company’s stockholders at the Special Meeting are set forth below: 1. Share Issuance Proposal. The proposal to approve the issuance of shares of Common Stock in connection with the Merger and in accordance with Nasdaq Listing Rules 5635(a) and 5635(b) was approved by the following votes: Votes For Votes Against Abstentions ─────────────────────────────────────────────────── 274,099,041 7,571,806 73,565 2. Charter Amendment Proposal. The proposal to approve an amendment to the Company’s Eighth Amended and Restated Certificate of Incorporation, as amended, to (i) effect a reverse stock split of the Company’s issued and outstanding Common Stock at a ratio in the range from 1-for-20 to 1-for-40, inclusive, with the final ratio to be mutually agreed to by the Company and Treeline Biosciences, Inc., and (ii) change the name of the Company to “Treeline Biosciences, Inc.” was approved by the following votes: Votes For Votes Against Abstentions ─────────────────────────────────────────────────── 275,584,914 6,123,396 36,102 3. Post-Closing Equity Incentive Plan Proposal. The proposal to approve the Post-Closing Equity Incentive Plan, which will become effective at the effective time of the Merger and is contingent on the closing of the Merger, was approved by the following votes: Votes For Votes Against Abstentions ─────────────────────────────────────────────────── 207,381,782 57,483,106 16,879,524 4. Post-Closing ESPP Proposal. The proposal to approve the Post-Closing Employee Stock Purchase Plan (as defined in the Proxy Statement/Prospectus), which will become effective at the effective time of the Merger and is contingent on the closing of the Merger, was approved by the following votes: Votes For Votes Against Abstentions ─────────────────────────────────────────────────── 224,903,287 39,976,090 16,865,035 5. Advisory Compensation Proposal. The proposal to approve, on a nonbinding, advisory basis, the Transaction-Related Compensation (as defined in the Proxy Statement/Prospectus) was approved by the following votes: Votes For Votes Against Abstentions ─────────────────────────────────────────────────── 248,805,322 15,966,136 16,972,954 6. Element Mass Cytometry Divestiture Proposal. The proposal to approve the Element Mass Cytometry Divestiture (as defined in the Proxy Statement/Prospectus), which may be considered a sale of substantially all of the assets of the Company under Section 271 of the Delaware General Corporation Law, was approved by the following votes: Votes For Votes Against Abstentions ─────────────────────────────────────────────────── 276,299,544 5,336,020 108,848 7. Adjournment Proposal. The proposal to approve adjournments of the Special Meeting from time to time, if necessary or appropriate, to solicit additional proxies in favor of the Share Issuance Proposal and/or the Charter Amendment Proposal if there are insufficient votes at the time of such adjournment to approve such proposals or to ensure that any supplement or amendment to the Proxy Statement/Prospectus is timely provided to the Company’s stockholders was approved by the following votes: Votes For Votes Against Abstentions ─────────────────────────────────────────────────── 255,788,813 9,049,389 16,906,210 There were no broker non-votes with respect to any of the proposals.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On November 19, 2026, the Company issued a press release announcing that its stockholders voted to approve all proposals at the Special Meeting. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in this Item 7.01 by reference. The information set forth in this Item 7.01 and in the attached Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 (by filename) ef20085888_ex99-1.htm

Exhibit 99.1 Standard BioTools Stockholders Approve All Proposals Related to Merger with Treeline Biosciences and Sale of Mass Cytometry Business BOSTON, Mass., Nov. 19, 2026 - Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced that, at its Special Meeting of Stockholders held earlier today, stockholders approved all proposals related to the Company’s previously announced merger with Treeline Biosciences, Inc. (“Treeline”) and the sale of its Mass Cytometry business to Element Biosystems, LLC, an acquisition vehicle formed by GMT Venture Partners, LLC. “We are pleased with the outcome of today’s vote and thank our stockholders for their support of these transactions,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “These approvals represent an important step toward completing our planned merger with Treeline and positioning our Mass Cytometry business for continued success under new ownership. We look forward to completing both transactions.” The merger with Treeline is expected to close in the fourth quarter of 2026, subject to the satisfaction of remaining customary closing conditions. The sale o…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.